Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty - PubMed
4 days ago
- #Brentuximab vedotin
- #Geriatric oncology
- #DLBCL
- Study evaluates Brentuximab vedotin (BV) combined with dose-attenuated chemoimmunotherapy (R-miniCHP) in patients aged 75+ with diffuse large B-cell lymphoma (DLBCL).
- Geriatric assessments (GA) and frailty evaluations (using DAFI) were integrated to assess physiologic health.
- 22 patients (median age 77.5) were enrolled; 77.3% completed six cycles of BV-R-miniCHP.
- Overall response rate (ORR) was 85.7%, with 71.4% achieving complete response (CR).
- Two-year progression-free survival (PFS) was 63.6%, with no significant difference by CD30 status or frailty (DAFI score).
- Hematologic toxicities and infections were common grade ≥3 adverse events; 45% reported serious adverse events.
- Two deaths occurred during treatment, but the regimen was deemed feasible for older adults with DLBCL.